Background. We hypothesized that the effect of pimobendan (UD-CG 115 BS) to increase calcium
F_ or treatment of chronic heart failure, many types of positive inotropic agents, especially cyclic adenosine monophosphate (cAMP)-phosphodiesterase (PDE) inhibitors such as amrinone and milrinone, have been developed as alternative drugs to cardiac glycosides and catecholamines.' However, recent studies have shown that these PDE inhibitors are accompanied by similar increases in cardiac oxygen consumption (Vo2) to catecholamines when they enhance contractility to the same extent. 23 In these energetic aspects, PDE inhibitors do not seem to be superior to catecholamines.
contractility, oxygen cost * myofilament, Ca2P imobendan (UD-CG 115 BS), a pyridazinone benzimidazole derivative, inhibits cAMP-PDE,4 prolongs the action potential duration of twitching myocardium,5 and increases the calcium sensitivity of contractile proteins in skinned guinea pig, dog, and failing human cardiac muscle fibers.5-7 These results suggest that pimobendan could produce higher contractility than other positive inotropic agents that have no Ca2'-sensitizing effect at any levels of intracellular Ca2' concentration; through an increase in Ca2' sensitivity, pimobendan might result in less Vo2 for increased contractility compared with other positive inotropic agents without Ca2+-sensitizing effect.
Holubarsch et al8 found that pimobendan increased myocardial oxygen consumption less than isoproterenol for a given increase in force-time integral in guinea pig papillary muscles and human idiopathic dilated cardiomyopathy hearts.910 However, they did not find that pimobendan had an advantage over cardiac glycosides in contractile economy.8 Because they only studied the effect of pimobendan on contractile economy and not on contractile efficiency and oxygen cost of contractility, the cardiac energetic advantage of pimobendan has not been fully studied.
The purpose of this study was to assess the effects of pimobendan on left ventricular (LV) contractility and energetics in comparison with dobutamine by using our concept of Em., (ventricular contractility index) and pressure-volume area (PVA, a measure of the total mechanical energy yielded by the LV). Dobutamine does not alter the contractile efficiency.1" We examined whether pimobendan alters the contractile efficiency of the LV and whether the oxygen cost of Em,,, with pimobendan is smaller than with dobutamine in the blood-perfused dog heart.
Methods

Surgical Preparation
We used the excised, cross-circulated dog heart preparation as previously described in detail. 21 13 Briefly, two mongrel dogs (weight, 12-22 kg) were anesthetized with sodium pentobarbital (30 mg/kg i.v.) after premedication with ketamine hydrochloride (5 mg/kg i.m.).
Both dogs were heparinized (1,000 units/kg). The left subclavian artery and the right ventricle (RV) of the donor dog heart were cannulated and connected to the common carotid arteries and the external jugular vein of the support dog, respectively. The heart of the donor dog was excised from the chest after cross-circulation was started so that there was no interruption of coronary circulation. Systemic hypotension under crosscirculation was prevented with diphenhydramine hydrochloride (30-60 mg i.m.) and indomethacin (0.5-1.0 mg/kg i.v.).
A thin, latex balloon (unstressed volume, 60 ml) with a miniature pressure transducer (model P-7, Konigsberg Instruments, Pasadena, Calif.) was placed in the LV. The balloon was connected to a servo pump (International Servo Data, Tokyo), with which we were able to precisely control and accurately measure instantaneous LV volume. The weight and presented as mm Hg-ml`* 100 g.14 The
Tma,x was determined as the time to Ema,, from the rising phase of R wave of ECG (end diastole). The dP/dtma, was determined as the positive maximum value of the first derivative of P(t). Relaxation. The time course of LV relaxation was assessed by three indexes: -dP/dtmax, time to -dP/dtma,c, and r. The -dP/dtmax (mm Hg/sec) is the peak rate of LV pressure decay, determined as the negative maximum of the first derivative of P(t). Time to -dP/dtm (msec) is the time to -dP/dtma,, from end diastole. ris the time constant of LV pressure decay during the relaxation phase. r was calculated as the reciprocal of the negative slope of the ln P(t) versus time relation, using the digitized data from the time of -dP/dtmax until LV pressure fell to 5 mm Hg above the end-diastolic pressure. Pressure-volume area (PVA). The PVA is the area circumscribed by the end-systolic pressure-volume (P-V) relation line, the end-diastolic P-V curve, and the systolic P-V trajectory ( Figure 1A ).12-4 The PVA represents the total mechanical energy generated by each contraction of the LV. We calculated PVA of each beat from the digitized P(t) and V(t) data in the same way as before.12'3 The PVA was normalized for 100 g LV, and its dimensions are mm Hg * ml* beat-* 100 g`l.
Oxygen consumption. The Vo2 was obtained as the product of CBF and arteriovenous oxygen content difference. It was divided by heart rate to obtain Vo2 per beat in steady state. To minimize the contribution of RV Vo2 to the measured total Vo2, we kept the RV collapsed by continuous hydrostatic drainage of the coronary venous blood. The collapsed RV was assumed to have virtually zero PVA and hence no PVA-dependent Vo2. The RV component of PVA-independent Vo2 was calculated by multiplying biventricular PVA-independent Vo2 in each contractile state with (RV weight)/(LV+RV weight).12-'4 The RV PVA-independent Vo2 was subtracted from the total Vo2 to yield LV Vo2. At the end of each experiment, the LV including the septum and the RV free wall were weighed. They were 80.2+11.6 g (SD) and 24.4+6.3 g, respectively.
Vo2-PVA relation. Because 
Results
Control Volume Run
The control Emaxvalue was 4.0±1.6 mm Hg* ml-l* 100 g in all pooled 12 hearts. In every tested heart, Vo2 increased linearly with PVA with a correlation coefficient close to unity (0.987±0.008) in the control contractile state. The slope (a) and Vo2 intercept (b) of the control Vo2-PVA relation were 1.665±0.330x10`5 ml 02 mm Hg-1 * ml-l and 0.0218±0.0029 ml 02* beat`. 100 g-1, respectively. There was no significant difference between the dobutamine-first and pimobendan-first groups in E,,,, correlation coefficient, or a or b. Figure 3 shows representative tracings of LV isovolumic pressure, volume, ECG, and coronary arteriovenous oxygen content difference during the pimobendan inotropism run in a representative heart in the dobutamine-first group. Pimobendan infusion increased Ema,, from 6.1 to 10.5 mm Hg . ml-'l beat`* 100 g, PVA from 706 to 1,202 mm Hg . ml * 100 g-1, and Vo2 from 0.037 to 0.052 ml 02* beat-. 100 g`. All other hearts showed similar results to this heart. Figure 4 . In this heart, PVA-independent Vo2 increased linearly with increases in Em with correlation coefficients close to unity (0.984 for dobutamine and 0.991 for pimobendan). The two inotropism runs yielded nearly superimposable linear regression lines. The oxygen cost of Emax was almost the same (0.00190 versus 0.00160 ml 02 *ml * mm Hg`* beat.*100 g-2)
Dobutamine and Pimobendan Runs
for dobutamine and pimobendan in this heart.
Similar linear PVA-independent Vo2-Ema. relations to Figure 5A were obtained for dobutamine and pimobendan in all other 11 hearts. Correlation coefficients of the relation were close to unity (median, 0.957 for dobutamine and 0.964 for pimobendan). ANCOVA showed no significant difference in their slopes (oxygen cost of Em,,) between dobutamine and pimobendan in eight of 12 hearts. Three of the other four hearts had about 1.4 times greater oxygen cost of Em.. for pimobendan than for dobutamine, whereas the remaining one heart had a twice-greater oxygen cost of Em.x for dobutamine than for pimobendan. Figure 5B compares mean values for oxygen cost of Emax with dobutamine and pimobendan in all 12 hearts. There was no significant difference in oxygen cost of Em.. between the two drugs (0.00209±0.00068 ml 02 ml* mm Hg`1 beat`* 100 g-2 versus 0.00207±0.00094 ml 02 * ml -mm Hg`*beat-. 100 g-2). (12,873+±4,607 g. sec/mi 02 for dobutamine and 14,323+4,290 g-sec/ ml 02 for pimobendan). Thus, pimobendan had a slightly but significantly greater contractile economy than dobutamine after the comparable enhancement of Emax, although the contractile efficiency was similar between the two drugs.
Propranolol-Pimobendan Run
The Emax decreased from 6.6+±4.4 mm Hg* ml-* 100 g at control to 3.3±+1.6 mm Hg* ml -* 100 g by P-adrenergic receptor blockade with propranolol. Under P-blockade, pimobendan infusion at a constant concentration of about 1 ,M enhanced E, to 6.1+ 3.3 mm Hg* ml-l * 100 g, which was similar to the prepropranolol control level. This result indicates that the positive inotropic effect of pimobendan is not due to a stimulation of the 13-adrenergic receptor system. In the pimobendan inotropism run, CBF was greater (74±21 ml/min for control versus 113±43 ml/min for pimobendan), anid CPP 
Circulating Catecholamines
Epinephrine and norepinephrine concentrations in the support dog's arterial blood did not significantly change before and after the pimobendan inotropism run (epinephrine, from 0.74+0.69 ng/ml to 1.00±0.87 ng/ ml; norepinephrine, from 0.86+0.51 ng/ml to 1.23+0.73 ng/ml). This result indicates that the mechanoenergetic effects of pimobendan were not contaminated by catecholamines released from the support dog.
KCl Arrest
Basal metabolic Vo0 during KCI arrest was 1.30+0.36 ml 02 *min' 100 g`1 for pooled data (nine hearts) and 1.32±0.31 ml 02* mim-1 100 g`1 for the dobutaminefirst group, in which pimobendan was continuously infused into the hearts (five hearts). These basal metabolism values were close to our previously reported valuein normal canine left ventricles.'2 Thus, pimobendan did not influence Vo2 for basal metabolism. This result indicates that the elevation of the PVA-independent Y02 with pimobendan was primarily due to an increase in
Vo0 for E-C coupling. known to decrease it, we expected that the oxygen cost of Em,, of pimobendan would be smaller than that of dobutamine; pimobendan would consume less Vo2 than dobutamine in increasing contractility to the same level.
However, we found almost the same oxygen cost of Ema.
between pimobendan and dobutamine. Why did we find the same energy cost of contractility for the two drugs?
In the pimobendan inotropism run, the cumulative concentration of pimobendan in the support dog was only 0.07 ,uM on average in the middle of the pimobendan run, although we continuously infused pimobendan into the coronary arterial tube at a level of about 1 ,uM. This indicates that the concentration of pimobendan entering into the excised heart was virtually constant throughout the run regardless of recirculation of pimobendan from the support dog. Even with pimobendan at about 1 ,sM, we were able to enhance LV contractility to the same level as dobutamine. The calcium-sensitizing effect of pimobendan is reported to appear at 50-100 ,M in skinned cardiac muscles.6'20 However, such a high concentration of pimobendan is far out of We also calculated the ratio of the increase in PTI to the increase in Emax (APTI/AEmax) in the dobutamine and pimobendan inotropism runs at a matched enddiastolic volume. Figure 7 shows mean PTI and Em,, values before and after dobutamine and pimobendan.
The APTI/AEm;,X was slightly but significantly greater with pimobendan (2.35+0.82 sec. ml* 100 g LV) than with dobutamine (2.12±0.85 sec. ml* 100 g LV, p<0.05). This finding, together with slightly longer Tmax value of pimobendan than dobutamine (Table 1) , indicates that pimobendan facilitates maintenance of tension more than dobutamine for a given positive inotropic effect. This effect might reflect the Ca21-sensitizing effect of pimobendan.
The other difference between pimobendan and dobutamine is the greater coronary vasodilating effect of pimobendan than that of dobutamine at the same level of enhanced contractility. Furthermore, in the propranolol-pimobendan inotropism run, the restoration of the control contractility level with pimobendan was accompanied by increased coronary flow above control. Recently, Goto et a127 have shown that a doubled coronary flow with adenosine at a constant perfusion pressure increases Emax by 18% (Gregg's phenomenon27) and produces a parallel upward shift of the Vo2-PVA relation. Therefore, it seems that the enhanced contractility with pimobendan was attributable at least in part to the increased coronary flow, or Gregg's phenomenon, besides inhibition of cAMP-PDE. In the study by Goto et al,27 coronary hyperemia did not abbreviate the duration of contraction (personal communication), which is in contrast to catecholamines. Thus, the potent coronary vasodilating effect of pimobendan could be another factor that produced larger PTI and FTI than dobutamine at matched Ema,, and Vo2 without changing the contractile efficiency.
The results of this study may have an important pathophysiological significance. Most diseased hearts accompany contractile dysfunction with not only insufficient tension development but also relaxation disturbance. In the present study, pimobendan maintained tension longer than dobutamine for a given positive inotropic effect without impairing relaxation. This tension-maintaining effect would enable pimobendan to be a positive inotropic drug superior to catecholamines in treating heart failure. A result from a recent clinical study that has indicated the beneficial effect of pimobendan on exercise tolerance and quality of life in patients with heart failure28 might have come from the tension-maintaining effect of pimobendan. However, the actual difference in PTI between pimobendan and dobutamine at the comparably enhanced Emax was only 6.2±9.8% in the present study in the normal heart.
Further studies in failing hearts will be needed to determine whether the surplus in tension maintenance with pimobendan is pathophysiologically meaningful or clinically beneficial.
We have recently found that the oxygen cost of contractility with CaCI2 was 1.5 times29 and 2.2 times12 higher, respectively, in acidotic and stunned hearts than in normal hearts. Both acidotic and stunned hearts are known to have decreased Ca21 sensitivity.303' In addition, Lee and Allen32 have recently reported that EMD 53998, a new Ca2+ sensitizer, has more potent Ca2+-sensitizing effect than pimobendan. Studies using these failing heart models and purer Ca2' sensitizers may clarify the energetic significance of increasing Ca2+ sensitivity on oxygen cost of contractility in the future.
Summary
We assessed the effects of pimobendan and dobutamine on LV mechanoenergetics using the frameworks of Ema, and the Vo2-PVA relation in the excised, cross-circulated dog heart. Pimobendan exerts a positive inotropic effect even under ,-blockade and has a greater coronary vasodilating effect than dobutamine, reflecting a different positive inotropic mechanism from catecholamines. However, both drugs have the same contractile efficiency, although pimobendan has a slightly greater contractile economy. In addition, the oxygen costs of contractility of the two drugs are the same. Therefore, the energetic effects of the two drugs are similar regardless of the different positive inotropic mechanisms, i.e., despite the known Ca2+-sensitizing effect of pimobendan in blood-perfused, nonfailing dog hearts.
